Ulf Wiinberg

Mr. Ulf Wiinberg currently serves as the Chief Executive Officer of X-Vax Technology, Inc., a pre-clinical vaccine research company. He is also on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, and Alfa Laval AB, a Swedish industrial company. Prior to X-Vax, Mr. Wiinberg served as Chief Executive Officer of H. Lundbeck A/S from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several health care industry associations and held multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies, which was acquired by Pfizer in 2009. He acted there as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK; and in various commercial positions. Mr. Wiinberg brings to our board almost 20 years of senior leadership experience and experience in the biotechnology, pharmaceutical and healthcare industries internationally.